These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

231 related articles for article (PubMed ID: 6691664)

  • 1. Five-year surveillance of aminoglycoside usage in a university hospital.
    Betts RF; Valenti WM; Chapman SW; Chonmaitree T; Mowrer G; Pincus P; Messner M; Robertson R
    Ann Intern Med; 1984 Feb; 100(2):219-22. PubMed ID: 6691664
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Susceptibility of aerobic gram-negative bacilli to aminoglycosides. Effects of 45 months of amikacin as first-line aminoglycoside therapy.
    Saavedra S; Vera D; Ramírez-Ronda CH
    Am J Med; 1986 Jun; 80(6B):65-70. PubMed ID: 3014877
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antibiotic resistance patterns during aminoglycoside restriction.
    Young EJ; Sewell CM; Koza MA; Clarridge JE
    Am J Med Sci; 1985 Dec; 290(6):223-7. PubMed ID: 3936358
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Surveillance of aminoglycoside resistance. European data.
    Van Landuyt HW; Boelaert J; Glibert B; Gordts B; Verbruggen AM
    Am J Med; 1986 Jun; 80(6B):76-81. PubMed ID: 3089007
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Aminoglycoside resistance and aminoglycoside usage: ten years of experience in one hospital.
    Gerding DN; Larson TA; Hughes RA; Weiler M; Shanholtzer C; Peterson LR
    Antimicrob Agents Chemother; 1991 Jul; 35(7):1284-90. PubMed ID: 1929283
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Aminoglycoside resistance in gram-negative bacilli during increased amikacin use. Comparison of experience in 14 United States hospitals with experience in the Minneapolis Veterans Administration Medical Center.
    Gerding DN; Larson TA
    Am J Med; 1985 Jul; 79(1A):1-7. PubMed ID: 4025364
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Control of emergence of multi-resistant gram-negative bacilli by exclusive use of amikacin.
    Ruiz-Palacios GM; Ponce de Leon S; Sifuentes J; Ponce de Leon S; Calva JJ; Huazano F; Ontiveros C; Ojeda F; Bobadilla M
    Am J Med; 1986 Jun; 80(6B):71-5. PubMed ID: 3089006
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Progressive increase in antibiotic resistance of gram-negative bacterial isolates. Walter Reed Hospital, 1976 to 1980: specific analysis of gentamicin, tobramycin, and amikacin resistance.
    Cross AS; Opal S; Kopecko DJ
    Arch Intern Med; 1983 Nov; 143(11):2075-80. PubMed ID: 6639227
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Aminoglycoside antibiotics from clinical viewpoint].
    Lüthy R
    Int J Clin Pharmacol Biopharm; 1975 Mar; 11(2):112-25. PubMed ID: 1095500
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prevalence and mechanisms of aminoglycoside resistance. A ten-year study.
    Phillips I; King A; Shannon K
    Am J Med; 1986 Jun; 80(6B):48-55. PubMed ID: 3728534
    [TBL] [Abstract][Full Text] [Related]  

  • 11. An evaluation of the susceptibility patterns of gram-negative organisms isolated in cancer centres with aminoglycoside usage.
    Muscato JJ; Wilbur DW; Stout JJ; Fahrlender RA
    J Antimicrob Chemother; 1991 May; 27 Suppl C():1-7. PubMed ID: 1906860
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Alterations in the microbial flora and in the incidence of bacteremia at a university hospital after adoption of amikacin as the sole formulary aminoglycoside.
    King JW; White MC; Todd JR; Conrad SA
    Clin Infect Dis; 1992 Apr; 14(4):908-15. PubMed ID: 1576287
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Resistance surveillance programs and the incidence of gram-negative bacillary resistance to amikacin from 1967 to 1985.
    Gerding DN; Larson TA
    Am J Med; 1986 Jun; 80(6B):22-8. PubMed ID: 3089003
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The aminoglycosides: streptomycin, kanamycin, gentamicin, tobramycin, amikacin, netilmicin, and sisomicin.
    Edson RS; Terrell CL
    Mayo Clin Proc; 1987 Oct; 62(10):916-20. PubMed ID: 3657309
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The aminoglycosides. Streptomycin, kanamycin, gentamicin, tobramycin, amikacin, netilmicin, sisomicin.
    Edson RS; Keys TF
    Mayo Clin Proc; 1983 Feb; 58(2):99-102. PubMed ID: 6823164
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tobramycin, amikacin, sissomicin, and gentamicin resistant Gram-negative rods.
    Drasar FA; Farrell W; Maskell J; Williams JD
    Br Med J; 1976 Nov; 2(6047):1284-7. PubMed ID: 1000196
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Characteristics of gentamicin resistance in nosocomial infections.
    John JF; Rubens CE; Farrar WE
    Am J Med Sci; 1980; 279(1):25-30. PubMed ID: 6768292
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [The antimicrobial activity of amikacin in comparison with three other aminoglycoside-antibiotics (author's transl)].
    Jotzoff M
    Med Klin; 1978 Jun; 73(24):914-7. PubMed ID: 661734
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment of pediatric infections with amikacin as first-line aminoglycoside.
    Shulman ST; Yogev R
    Am J Med; 1985 Jul; 79(1A):43-50. PubMed ID: 4025367
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Nosocomial consequences of antibiotic usage.
    Giamarellou H; Touliatou K; Koratzanis G; Petrikkos G; Kanellakopoulou K; Lelekis M; Pagona A; Tsagarakis J; Symeonides J; Falagas M
    Scand J Infect Dis Suppl; 1986; 49():182-8. PubMed ID: 3103210
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.